摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(EtO2C)2CH2 | 77736-16-4

中文名称
——
中文别名
——
英文名称
(EtO2C)2CH2
英文别名
Ethoxycarbonyloxymethyl ethyl carbonate
(EtO2C)2CH2化学式
CAS
77736-16-4
化学式
C7H12O6
mdl
——
分子量
192.169
InChiKey
AQOPXLHJPZLDAL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    71.1
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    (EtO2C)2CH2 、 1-(4-(bromomethyl)phenoxy)-2-chloro-4-(trifluoromethyl)benzene 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成
    参考文献:
    名称:
    3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists
    摘要:
    The design, synthesis, and structure-activity relationship (SAR) for a series of beta-substituted 3-(4-aryloxyaryl) propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.03.114
点击查看最新优质反应信息

文献信息

  • 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists
    作者:Shawn P. Walsh、Alexandra Severino、Changyou Zhou、Jiafang He、Gui-Bai Liang、Carina P. Tan、Jin Cao、George J. Eiermann、Ling Xu、Gino Salituro、Andrew D. Howard、Sander G. Mills、Lihu Yang
    DOI:10.1016/j.bmcl.2011.03.114
    日期:2011.6
    The design, synthesis, and structure-activity relationship (SAR) for a series of beta-substituted 3-(4-aryloxyaryl) propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model. (C) 2011 Elsevier Ltd. All rights reserved.
查看更多